In the pipeline: TNX-650
Today's featured lymphoma treatment in the pipeline is the monoclonal antibody TNX-650.
Name: TNX-650
Class: Humanized monoclonal antibody
Type: Biological therapy
FDA to date: NA
Manufacturer: Tanox (acquired by Genentech in 2007)
Indications: Hodgkin lymphoma refractory to radiation or chemotherapy.
A few words: TNX-650 is believed to work by binding and blocking the activity of interleukin-13 (IL-13), which is a mediator in allergic inflammation and may contribute to cell proliferation in Hodgkin patients and bear some responsibility in the ability of the disease to dodge the effects of radiation and chemotherapy. This drug is currently in phase I/II trials and far away from seeing the light of the market, if ever.
Click here to see clinical trials involving TNX-650.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
